There are currently only two types of HIV drug resistance tests.
HIV Education > HIV Clinical Updates > Previous Version
This section includes brief bulletins about topics of interest to those involved in the field of HIV resistance.
(Release date: July 13, 2010)
CROI 2010: Resistance Update #6. Decrease prevalence of drug resistance mutations in a large, multisite cohort (2002-2008)
Read more...(Release date: June 28, 2010)
CROI 2010: Resistance Update #5. NA-ACCORD: estimating the prevalence of multidrug resistance in North America.
Read more...(Release date: June 14, 2010)
CROI 2010: Resistance Update #4. Tracking transmitted drug resistance-associated mutations among recent and long-standing HIV infection.
Read more...(Release date: June 1, 2010)
CROI 2010: Resistance Update #3. Is behavioral risk reduction sustained over the long-term?
Read more...(Release date: May 11, 2010)
CROI 2010: Resistance Update #2. Raltegravir genetic resistance patterns in HIV-2 patients.
Read more...(Release date: March 30, 2010)
(Release date: March 30, 2010)
CROI 2010: Resistance Update #1. Resistance-associated mutations to etravirine in non-B HIV-1 subtypes.
Read more...(Release date: November 16, 2009)
An analysis of the relative contributions of specific drugs to virological response.
Read more...(Release date: October 19, 2009)
Correlating virtual phenotype-LM with an independent phenotypic assay (van Houtte et al) and recent enhancements to virco®TYPE HIV-1 analyses (Winters et al).
Read more...(Release date: April 22, 2009)
Nine-year trends in clinically relevant reduced susceptibility of HIV-1 to antiretrovirals.
Read more...HIV9 Meeting Glasgow Scotland (Release date: Jan. 19, 2009)
The failure of some patients to fully respond to antiretroviral treatment regimens despite having viruses predicted as susceptible by genotypic analysis can present a clinical conundrum.
Read more...2008 ICAAC/IDSA Meeting (Release date: Nov. 17, 2008)
Phenotype-based HIV resistance testing provides valuable information to help guide the selection of treatment regimens, particularly in patients with likely resistance to one or more ARVs.
Read more...2008 International HIV Drug Resistance Workshop (Release date: Jul. 14, 2008)
Phenotypic susceptibility to the first generation NNRTIs (efavirenz and nevirapine) is significantly affected by single mutations in the HIV viral genome.
Read more...2008 Euro HIV Drug Resistance Workshop (Release date: Jun. 30, 2008)
The emergence of drug-resistant HIV strains is one of the key factors associated with suboptimal virologic response to antiretroviral therapy.
Read more...News from the 24th Annual Clinical Virology Symposium (Release date: Jun. 2, 2008)
The virco®TYPE HIV-1 v4.2.01 (vT) and the PhenoSense GTTM (PSGT) assays use different methods to account for such mixtures in patient samples undergoing evaluation for antiretroviral drug susceptibility.
Read more...A recent study demonstrates accurate prediction of drug susceptibility from viral genotype (Release date: May 27, 2008)
The VirtualPhenotypeTM-LM is a data-driven linear-regression modeling engine that provides an accurate prediction of the HIV resistance phenotype from the viral genotype.
Read more...News from the 6th European HIV Drug Resistance Workshop (Release date: May 10, 2008)
The interpretation of quantitative phenotypic resistance information via clinical cut-off values on the virco®TYPE HIV-1 report can assist HIV providers in optimizing combination antiretroviral therapy.
Read more...News from the 15th Conference on Retroviruses and Opportunistic Infections (Release date: Mar. 3, 2008)
Etravirine (TMC125), a new next-generation NNRTI, shows antiviral activity in treatment-experienced adult patients with HIV resistant to a NNRTI and other antiretroviral agents.
Read more...News from the 15th Conference on Retroviruses and Opportunistic Infections (Release date: Feb. 18, 2008)
Bart Winters and colleagues from Virco, presented data at the 15th Conference on Retroviruses and Opportunistic Infections on the development of virco®TYPE HIV-1 clinical cut-off values for etravirine based on treatment response data from etravirine phase II/III studies.
Read more...News from the 45th Annual Meeting of the Infectious Diseases Society of America (Release date: Dec. 03, 2007)
Current guidelines recommend the use of resistance tests to optimize the selection of active regimens when initiating or changing antiretroviral therapy.
Read more...News from the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Release date: Sep. 26, 2007)
Earlier studies using a limited number of laboratory and clinical isolates demonstrated that the HIV-1 protease mutation I50L confers resistance to atazanavir and susceptibility to other protease inhibitors (PIs).
Read more...News from the 16th International HIV Drug Resistance Workshop (Release date: Sep. 06, 2007)
An important aspect of the development of any system that predicts response to antiretroviral therapy is its validation in a diverse clinical dataset not used for algorithm development.
Read more...News from the 23rd Clinical Virology Symposium (Release date: May. 24, 2007)
Karam Mounzer and colleagues from The Jonathan Lax Treatment Center, in collaboration with Virco, presented a poster at the 23rd Annual Clinical Virology Symposium evaluating concordance of drug-specific resistance in PhenoSense GTTM (PGT) and virco®TYPE HIV-1 (virtual phenotype, VP) and estimated the cost savings associated with introduction of VP assays into a community-based clinic.
Read more...News from the 5th European HIV Drug Resistance Workshop (Release date: May. 17, 2007)
The 5th European HIV Drug Resistance Workshop featured 7 important scientific contributions by researchers at Virco Labs.
Read more...What's New
These modules are presented in an easy to navigate format and begin with a history of the HIV/AIDS epidemic and current epidemiology.
November 2009
Volume 1, Number 3
Presented by Dr. Rafael E. Campo
A 49-year-old African American male, with a history of IDU, unexpectedly presents to the clinic with viremia and declining CD4 cell count after being lost to follow-up for 2.5 years..
Updated December 1, 2009 — Antiretroviral Guidelines for Adults and Adolescents: Drug Resistance Testing